Business Monitor International


Brazil Pharmaceuticals & Healthcare Report

Published 29 December 2014

  • 168 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Brazil Pharmaceuticals & Healthcare Report

BMI View: A thriving pharmaceutical market, active improvements to regulatory practices, and the government 's commitment to healthcare services will continue to make Brazil a regional outperformer. A growing population and strategies for improved clinical research will ensure the development of the Brazilian market. C ontinued domestic competition and the need for further regulatory change will still pose challenges.

Headline Expenditure Projections

Pharmaceuticals: BRL57.0bn (USD26.4bn) in 2013 to BRL62.0bn (USD26.6bn) in 2014; +8.8% in local currency terms and +0.8% in US dollar terms. Forecast has been maintained from Q414.

Healthcare: BRL449.4bn (USD208.2bn) in 2013 to BRL492.46bn (USD211.4bn) in 2014; +9.6% in local currency terms and +1.5% in US dollar terms. Forecast has been revised upward from Q414 due to changes in historical data

Risk/Reward Index: Brazil scores 60.3 in BMI's Pharmaceutical and Healthcare Risk/Reward Index (RRI), making it the fifth most attractive pharmaceutical market in the Americas. We highlight that Brazil will continue to be the most important market for multinationals in Latin America. Its position has been very well reflected by this quarter's RRR scores.

Key Trends And Developments

  • In November 2014, the Deputy Director of the China FDA confirmed an agreement with Brazil's National Health Surveillance Agency (ANVISA) to enhance bilateral cooperation on good manufacturing practices (GMPs) for pharmaceutical drugs.

  • In October 2014, ANVISA approved the interchangeability of similar drugs and branded medicines listed in the prescription.

  • In October 2014, Hovione announced that Asian countries such as India and China are expected to lose their status as global hubs for producing active pharmaceutical ingredients (APIs) due to the rising cost of wages and changing regulatory environments in developed countries, reports In-Pharma. Brazil was named as one country that would be a part of the second wave of emerging regions in...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Brazil 2010-2018)
15
Healthcare Market Forecast
16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Brazil 2010-2018)
18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Brazil 2010-2018)
18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Brazil 2010-2018)
19
Prescription Drug Market Forecast
20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Brazil 2010-2018)
21
Patented Drug Market Forecast
22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Brazil 2010-2018)
23
Generic Drug Market Forecast
24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Brazil 2010-2018)
29
OTC Medicine Market Forecast
30
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Brazil 2010-2018)
31
Pharmaceutical Trade Forecast
32
Table: Pharmaceutical Trade Data And Forecasts, USDmn (Brazil 2012-2018)
34
Table: Pharmaceutical Trade Data And Forecasts, BRLmn (Brazil 2012-2018)
35
Other Healthcare Data
36
Key Risks To BMI's Forecast Scenario
37
Macroeconomic Forecasts
38
Table: Brazil - Economic Activity
43
Industry Risk Reward Ratings
44
Americas Risk/Reward Ratings
44
Brazil Risk/Reward Ratings
50
Rewards
50
Risks
50
Market Overview
52
Industry Trends And Developments
53
Epidemiology
53
Rare Diseases
56
Compassionate Use Programmes
56
Healthcare Sector
57
Research & Development
61
Table: Brazilian Government's Partnership Deals With Multinationals
62
Biotechnology
65
Clinical Trials
72
Regulatory Development
74
Intellectual Property Regime
76
Counterfeit Drugs
79
Compulsory Licensing
80
Pricing Regime
81
Reimbursement Regime
84
OTC Regulations
87
Advertising
89
Protectionist Measures
89
Competitive Landscape
93
Table: Top 20 Pharmaceutical Companies In Brazil By Sales In 2010
93
Innovative Drugmakers
94
Generic Drugmakers
104
Table: Hypermarcas' Major Acquisitions, 2005-11
106
OTC Sector
108
Pharmaceutical Distribution Sector
109
Pharmaceutical Retail Sector
111
Company Profile
116
Ach-/Biosint-tica
116
EMS Sigma
120
Eurofarma
123
Medley
126
Crist-lia
129
Sanofi
132
Pfizer
136
Merck & Co
141
Novartis
145
GlaxoSmithKline
149
Table: GSK'S Strong Collaborative Efforts In Public-Private Partnerships (Ppps) In Brazil
152
Roche
153
Demographic Forecast
157
Table: Brazil's Population By Age Group, 1990-2020 ('000)
158
Table: Brazil's Population By Age Group, 1990-2020 (% of total)
159
Table: Brazil's Key Population Ratios, 1990-2020
160
Table: Brazil's Rural And Urban Population, 1990-2020
160
Glossary
161
Methodology
163
Pharmaceutical Expenditure Forecast Model
163
Healthcare Expenditure Forecast Model
163
Notes On Methodology
164
Risk/Reward Ratings Methodology
165
Ratings Overview
166
Table: Pharmaceutical Risk/Reward Ratings Indicators
166
Indicator Weightings
167

The Brazil Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Brazil Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Brazil pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Brazil, to test other views - a key input for successful budgeting and strategic business planning in the Brazilian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Brazilian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Brazil.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc